# Medra

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medra

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.medra.ai/
- Total disclosed funding: $52M
- Latest round: Series A (Dec 11, 2025)
- Investors on record: 8

## About

Based in the US, Medra is a technology company focused on automating laboratory processes through its innovative Continuous Science Platform that blends Physical AI and Scientific AI for enhanced research efficiency.Medra specializes in developing automated solutions for laboratory work, allowing scientists to conduct experiments with high precision. In December 2025, Medra raised USD 52 million in series A funding led by new investor Human Capital, with participation from other new investors NFDG Ventures, Catalio Capital Management, Menlo Ventures, 776, and Fusion Fund. Returning investors Lux Capital and Neo also participated in the round. Medra offers a comprehensive suite of products centered around its Continuous Science Platform, which integrates Physical AI and Scientific AI to provide an autonomous robotic system for laboratory work. This platform enables scientists to execute protocols in a manner akin to traditional scientific methods, with seamless integration of user-defined protocols and instruments. The system is designed to enhance productivity by allowing multiple experiments to be run in parallel across applications such as gene editing and microbial discovery. Medra caters to a diverse client base that includes academic institutions, biotech firms, and pharmaceutical companies who require precision and consistency in their research. The platform is operational across several global markets including North America, Europe, and parts of Asia, where it addresses the growing demand for automation in scientific research. Medra generates revenue through a business model centered on subscriptions and partnerships with research institutions and private companies. Clients typically engage with Medra for access to the Continuous Science Platform, which includes both software and hardware components tailored to specific research needs. Revenue streams include monthly or annual subscription fees for the platform, alongside potential transactional revenues from bespoke integrations or additional services. The pricing structure is designed to accommodate a variety of research budgets, allowing for scalable solutions that range from entry-level access to more comprehensive, high-throughput configurations. Key offerings include the AI-driven robotic systems that facilitate various laboratory protocols, ensuring Medra's position as a leader in lab automation solutions for its clientele. The company will use the December 2025 funding to scale its Physical AI platform, expand robotics and AI integration for drug discovery, and strengthen partnerships like Genentech to accelerate automated experiments and continuous learning.

## Funding rounds

- Series A, Dec 11, 2025, $52M — Menlo Ventures, Lux Capital, Fusion Fund, Neo Ventures, Human Capital, Catalio Capital Management, 776, NFDG Ventures

## Investors

- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series A
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A
- Fusion Fund (https://capitalatlas.ai/funds/fusion-fund) — Series A
- Neo Ventures — Series A
- Human Capital (https://capitalatlas.ai/funds/human-capital) — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A
- 776 (https://capitalatlas.ai/funds/776) — Series A
- NFDG Ventures (https://capitalatlas.ai/funds/nfdg-ventures) — Series A